The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma

BACKGROUND: There are limited reports on nanoparticle albumin bound‐paclitaxel (nab‐paclitaxel) regimens as second‐ or third‐line treatments for advanced esophageal squamous cell carcinoma (ESCC). Additionally, its safety and efficacy in ESCC patients after failure of first‐line programmed cell deat...

Descripción completa

Detalles Bibliográficos
Autores principales: Xin, Dao, Song, Yan, Mu, Lan, Zhang, Bo, Qi, Ling, Gao, Jing, Wang, Xingyuan, Xu, Jianping, Qu, Tao, Huang, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212655/
https://www.ncbi.nlm.nih.gov/pubmed/37035870
http://dx.doi.org/10.1111/1759-7714.14885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212655/
https://www.ncbi.nlm.nih.gov/pubmed/37035870
http://dx.doi.org/10.1111/1759-7714.14885

Ejemplares similares